A Plant Proteinase Inhibitor from Enterolobium contortisiliquum Attenuates Pulmonary Mechanics, Inflammation and Remodeling Induced by Elastase in Mice

Carregando...
Imagem de Miniatura
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI AG
Autores
THEODORO-JUNIOR, Osmar Aparecido
ALMEIDA-REIS, Rafael
OLIVA, Leandro Vilela
PRADO, Carla Maximo
LOBO, Yara Aparecida
Citação
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.18, n.2, article ID 403, 18p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Proteinase inhibitors have been associated with anti-inflammatory and antioxidant activities and may represent a potential therapeutic treatment for emphysema. Our aim was to evaluate the effects of a plant Kunitz proteinase inhibitor, Enterolobium contortisiliquum trypsin inhibitor (EcTI), on several aspects of experimental elastase-induced pulmonary inflammation in mice. C57/Bl6 mice were intratracheally administered elastase (ELA) or saline (SAL) and were treated intraperitoneally with EcTI (ELA-EcTI, SAL-EcTI) on days 1, 14 and 21. On day 28, pulmonary mechanics, exhaled nitric oxide (ENO) and number leucocytes in the bronchoalveolar lavage fluid (BALF) were evaluated. Subsequently, lung immunohistochemical staining was submitted to morphometry. EcTI treatment reduced responses of the mechanical respiratory system, number of cells in the BALF, and reduced tumor necrosis factor- (TNF-), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-12 (MMP-12), tissue inhibitor of matrix metalloproteinase (TIMP-1), endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS)-positive cells and volume proportion of isoprostane, collagen and elastic fibers in the airways and alveolar walls compared with the ELA group. EcTI treatment reduced elastase induced pulmonary inflammation, remodeling, oxidative stress and mechanical alterations, suggesting that this inhibitor may be a potential therapeutic tool for chronic obstructive pulmonary disease (COPD) management.
Palavras-chave
COPD, emphysema, proteinase inhibitor, EcTI
Referências
  1. de Paula CAA, 2012, J BIOL CHEM, V287, P170, DOI 10.1074/jbc.M111.263996
  2. Barnes PJ, 2005, EUR RESPIR J, V25, P1084, DOI 10.1183/09031936.05.00139104
  3. Batista IFC, 2001, ACTA CRYSTALLOGR D, V57, P602, DOI 10.1107/S0907444901001810
  4. Benetazzo MG, 1999, RESP MED, V93, P648, DOI 10.1016/S0954-6111(99)90105-1
  5. Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908
  6. Churg A, 2005, CURR OPIN PULM MED, V11, P153, DOI 10.1097/01.mcp.0000149592.51761.e3
  7. De Leo F, 2002, NUCLEIC ACIDS RES, V30, P347, DOI 10.1093/nar/30.1.347
  8. Deshmukh HS, 2005, AM J RESP CRIT CARE, V171, P305, DOI 10.1164/rccm.200408-1003OC
  9. Guarnieri F, 2010, P NATL ACAD SCI USA, V107, P10661, DOI 10.1073/pnas.1001349107
  10. Hanaoka M, 2011, CHEST, V139, P1101, DOI 10.1378/chest.10-0920
  11. Hantos Z, 2008, J APPL PHYSIOL, V105, P1864, DOI 10.1152/japplphysiol.90924.2008
  12. Ito S, 2004, J APPL PHYSIOL, V97, P204, DOI 10.1152/japplphysiol.01246.2003
  13. LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324
  14. Liu CY, 2013, ARCH BIOCHEM BIOPHYS, V535, P234, DOI 10.1016/j.abb.2013.02.013
  15. Lopes FDTQS, 2013, HISTOL HISTOPATHOL, V28, P269, DOI 10.14670/HH-28.269
  16. Luisetti M, 1996, EUR RESPIR J, V9, P1482, DOI 10.1183/09031936.96.09071482
  17. Mahadeva R, 2002, THORAX, V57, P908, DOI 10.1136/thorax.57.10.908
  18. Martins-Olivera B. T., 2016, MEDIAT INFLAMM, V2016
  19. Nakahata AM, 2011, BIOL CHEM, V392, P327, DOI 10.1515/BC.2011.031
  20. Neuhof C, 2003, BIOL CHEM, V384, P939, DOI 10.1515/BC.2003.105
  21. Oliva MLV, 2009, AN ACAD BRAS CIENC, V81, P615, DOI 10.1590/S0001-37652009000300023
  22. Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137
  23. Owen Caroline A, 2008, Int J Chron Obstruct Pulmon Dis, V3, P253
  24. Pauwels RA, 2004, LANCET, V364, P613
  25. Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
  26. Sakoda CPP, 2016, ACTA HISTOCHEM, V118, P615, DOI 10.1016/j.acthis.2016.07.001
  27. Pigati PA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0073-4
  28. Plantier L, 2007, AM J PHYSIOL-LUNG C, V293, pL1230, DOI 10.1152/ajplung.00460.2006
  29. Prado CM, 2005, AM J PHYSIOL-LUNG C, V289, pL677, DOI 10.1152/ajplung.00010.2005
  30. RighettI RF, 2014, RESP PHYSIOL NEUROBI, V192, P134, DOI 10.1016/j.resp.2013.12.012
  31. Scuri M, 2000, J APPL PHYSIOL, V89, P1397
  32. Selman M, 2003, CHEST, V123, P1633, DOI 10.1378/chest.123.5.1633
  33. Shapiro S D, 2003, Eur Respir J Suppl, V44, p30s
  34. Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4
  35. Shapiro SD, 2000, CHEST, V117, p223S, DOI 10.1378/chest.117.5_suppl_1.223S
  36. Suzuki M, 2009, AM J PHYSIOL-LUNG C, V296, pL614, DOI 10.1152/ajplung.90443.2008
  37. Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
  38. WEIBEL ER, 1963, LAB INVEST, V12, P131
  39. Wright JL, 2003, EUR RESPIR J, V22, P77, DOI 10.1183/09031936.03.00095703